![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
‘1104 (IRL201104) is a first-in-class immune-resetting peptide, which is being evaluated in phase 2 clinical trials for the treatment of eosinophilic esophagitis (EoE).
Lead Product(s): IRL201104
Therapeutic Area: Gastroenterology Product Name: ‘1104
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2024
Details:
‘1104 (IRL201104), a first-in-class peptide that is involved in resetting the immune system, has recently advanced through two Phase 2a trials; one in patients with eosinophilic esophagitis and one in patients with allergen sensitivity.
Lead Product(s): IRL201104
Therapeutic Area: Immunology Product Name: ‘1104
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2023
Details:
‘1104 (IRL201104), a first-in-class peptide that is involved in resetting the immune system, has recently advanced through two Phase 2a trials; one in patients with eosinophilic esophagitis and one in patients with allergen sensitivity.
Lead Product(s): IRL201104
Therapeutic Area: Gastroenterology Product Name: ‘1104
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2023
Details:
‘1104 (IRL201104), a first-in-class peptide that is involved in resetting the immune system, has recently advanced through two Phase 2a trials; one in patients with eosinophilic esophagitis and one in patients with allergen sensitivity.
Lead Product(s): IRL201104
Therapeutic Area: Gastroenterology Product Name: ‘1104
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2023
Details:
1104 (IRL201104) was derived from a natural immune-regulatory protein, Mycobacterium tuberculosis Chaperonin 60.1, involved in resetting the immune system. 1104 for the treatment of patients with eosinophilic esophagitis (EoE) and allergic disease.
Lead Product(s): IRL201104
Therapeutic Area: Gastroenterology Product Name: ‘1104
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2023
Details:
1104 (IRL201104) was derived from a natural immune-regulatory protein, Mycobacterium tuberculosis Chaperonin 60.1, involved in resetting the immune system. 1104 for the treatment of patients with eosinophilic esophagitis (EoE) and allergic disease.
Lead Product(s): IRL201104
Therapeutic Area: Gastroenterology Product Name: ‘1104
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2023
Details:
1104 (IRL201104) is a first-in-class peptide derived from a natural immune-regulatory protein, mTB Chaperonin 60.1 that is involved in resetting the immune system. Currently developed for eosinophilic esophagitis and allergen sensitivity.
Lead Product(s): IRL201104
Therapeutic Area: Immunology Product Name: ‘1104
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2023
Details:
1104 (IRL201104) was derived from a natural immune-regulatory protein, Mycobacterium tuberculosis Chaperonin 60.1, involved in resetting the immune system. 1104 for the treatment of patients with eosinophilic esophagitis (EoE) and allergic disease.
Lead Product(s): IRL201104
Therapeutic Area: Gastroenterology Product Name: ‘1104
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
‘1104 (IRL201104) is a peptide derived from a natural immune-regulatory protein and has recently completed Phase 2 clinical trial for patients with EoE with topline data expected in early 2023.
Lead Product(s): IRL201104
Therapeutic Area: Gastroenterology Product Name: ‘1104
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2022
Details:
1104, (IRL201104) a protein and a peptide respectively, reset the immune system to prevent the chronic pro-inflammatory immune response that results in autoimmune or allergic disease.
Lead Product(s): IRL201104
Therapeutic Area: Immunology Product Name: ‘1104
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022